
Equity markets gave a mixed reaction to news that Pfizer had prevailed in the bidding war for anti-obesity drug manufacturer Metsera.
While shares in Metsera fell on the news there was a warmer reaction to Novo Nordisk withdrawing from the race to buy the company.